Our study aligns with this observation, suggesting that SHOC2 plays a vital role in the survival advantage of RAS mutants in multiple tumor types (Skin, Haemato-lymphoid) by working with mutated RAS. The gene discussed is SHOC2; the disease is neoplasm.